A pioneering clinical trial is underway to explore a potential treatment for Long Covid, a complex condition affecting millions worldwide. Scientists from Nova Southeastern University are investigating sipavibart, a long-acting monoclonal antibody, to address the condition's extensive symptoms. The multi-year research involves 100 patients and aims to provide hope for those suffering from post-viral complications. This groundbreaking study represents a significant step in understanding and potentially treating the debilitating effects of Long Covid.
May 05, 2025
US scientists to explore potential of antibody against Long Covid
"Long
Covid affects at least 65 million people worldwide" - Dr. John Redd, SILC
CEO
US
scientists are undertaking a clinical trial to decode the efficacy of a
long-acting antibody against Long Covid -- a condition that affects at least 65
million people worldwide.
Key
Points
1
First major clinical trial targeting comprehensive Long Covid treatment
2
Sipavibart antibody tested to potentially restore patient health
3
Multi-year research involving 100 patients approved by FDA
4
Nova Southeastern University leads innovative medical research
Long
Covid affects people after an infection caused by the SARS-CoV-2 virus. The
condition not properly defined yet presents with more than 200 symptoms.
The
team from the Nova Southeastern University (NSU) and the Schmidt Initiative for
Long Covid (SILC) announced that a clinical trial is underway to assess the
effectiveness and safety of sipavibart -- a long-acting monoclonal antibody
designed by British drugmaker AstraZeneca's to protect the condition.
The
team enrolled 100 patients in the multi-year research, reviewed and cleared by
the FDA earlier this year. It aims to improve patients Long Covid symptoms and
restore them to full health.
"Like
many multi-symptom, post-viral conditions, Long Covid is incredibly complicated
and thus little understood," said Nancy Klimas, director of the Institute
for Neuro-lmmune Medicine at NSU.
"Finding
a treatment will be life-changing for patients suffering from the myriad
symptoms of Long Covid," she added.
The
study will test whether the monoclonal antibody sipavibart -- approved for the
pre-exposure prophylaxis (prevention) of Covid-19 in Japan and the EU -- is
effective in treating Long Covid. The trial is one of three Long Covid
treatment trials expected to begin in 2025.
"Long
Covid affects at least 65 million people worldwide, and with more than 200
symptoms, the health impacts of the disease can be debilitating," said Dr.
John Redd, CEO of SILC.
"This
trial represents our overall commitment to addressing the most pressing health
challenges of our time. We're leveraging our research expertise to potentially
transform treatment options for millions suffering from Long Covid, advance
knowledge, and improve patient outcomes through innovative clinical
research," added Dr. Ken Dawson-Scully, NSU's senior vice president for
research and associate provost.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment